Arovella Therapeutics Ltd
ALA
Company Profile
Business description
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Contact
84 Hotham Street
Corporate One
PrestonVIC3072
AUST: +61 398636472
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
44
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks
ASX share ticks all the popular thematic boxes
The shares are overvalued as investors are overly excited about defence and gold exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.50 | 11.40 | 0.12% |
| CAC 40 | 8,341.26 | 17.50 | -0.21% |
| DAX 40 | 25,430.74 | 25.40 | 0.10% |
| Dow JONES (US) | 49,295.51 | 294.69 | -0.59% |
| FTSE 100 | 10,113.44 | 27.26 | -0.27% |
| HKSE | 26,848.47 | 239.99 | 0.90% |
| NASDAQ | 23,737.25 | 3.35 | 0.01% |
| Nikkei 225 | 53,549.16 | 1,609.27 | 3.10% |
| NZX 50 Index | 13,656.05 | 27.24 | -0.20% |
| S&P 500 | 6,968.36 | 8.91 | -0.13% |
| S&P/ASX 200 | 8,808.50 | 17.20 | 0.20% |
| SSE Composite Index | 4,138.76 | 26.53 | -0.64% |